Loading...
•
Sep 30, 2021
Equillium Q3 2021 Earnings Report
Equillium reported financial results for the third quarter of 2021 and provided clinical development updates.
Key Takeaways
Equillium announced plans to initiate a pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease. They also reported a decrease in proteinuria observed in a subgroup of patients with lupus following two doses of itolizumab and interim safety data from the first cohort of asthma patients in the Phase 1b EQUIP study.
Plans announced to initiate a pivotal study in first-line acute graft-versus-host disease.
Reported decrease in proteinuria observed in subgroup of patients with lupus following two doses of itolizumab.
Reported interim safety data from first cohort of asthma patients in Phase 1b EQUIP study.
Company reaffirms guidance for EQUIP Phase 1b topline data in Q4 2021, and updates guidance to commence acute GVHD pivotal study in early 2022 and for interim data from EQUALISE Phase 1b Type B lupus nephritis patients to mid-2022.
Forward Guidance
Equillium provided guidance for upcoming catalysts.
Positive Outlook
- EQUIP Phase 1b study: topline data in uncontrolled asthma expected Q4 2021
- Initiate pivotal study in first-line aGVHD expected early 2022
- EQUALISE Phase 1b study: interim data from Type B lupus nephritis patients expected mid-2022
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...